source
- Novo Nordisk launches Phase 3 trial of lower maintenance doses of oral Wegovy for obesityNovo Nordisk has begun a Phase 3, placebo-controlled study called OASIS 5 to evaluate two lower oral doses of its GLP-1 weight-loss drug Wegovy (semaglutide) in people who are obese or overweight.…
- Lawmakers urge FDA to enact new China policies after 3 gene therapy deathsThree fatalities occurring recently in China clinical trials have spurred two members of U.S. Congress to urge the FDA to enact new policies designed to protect American patients.BioSpace · 45m ago↗ source